Multifield International Holdings Limited

Multifield International Holdings Limited

HHKEX:898
0.86
HKD
+0.01
(+0.58%)
794.27MMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.26
0.42
0.09
0.32
0.72
0.07
0.37
0.06
0.32
0.33
0.34
0.34
0.34
- -
Basic EPS, GAAP
0.85
0.57
0.79
0.62
0.78
0.88
0.64
0.01
0.5
0.32
0.21
0.28
-0.77
- -
Free Cash Flow per Basic Share
-0.43
0.24
-0.49
-0.02
0.36
0.26
0.5
0.04
0.23
0.18
0.21
-0.11
0.21
- -
Dividend per Share
0.06
0.06
0.06
0.06
0.07
0.07
0.07
0.01
0.04
0.04
0.04
0.04
0.04
- -
Book Value per Share
5.32
5.76
6.32
6.79
7.75
8.37
8.86
9.07
9.66
9.48
9.64
9.7
9.13
9.23
Tangible Book Value per Share
5.32
5.76
6.32
6.79
7.75
8.37
8.85
9.07
9.66
9.48
9.64
9.7
9.13
9.23
Basic Weighted Avg Shares
836
836
836
836
836
836
836
4,180
836
836
836
836
836
836
Sales/Revenue/Turnover
216
353
77
264
604
56
313
252
268
274
284
286
287
- -
Operating Margin (%)
66.78
93.47
-2.21
66.35
83.29
-77.1
73.01
66.17
69.23
72.81
71.42
68.81
69.87
- -
Depreciation Expense
3
6
6
7
8
7
5
4
3
3
3
3
3
- -
Net Income, GAAP
710
480
660
516
651
733
531
37
421
264
179
235
-645
- -
Effective Tax Rate (%)
8.26
7.47
29.29
22.3
1.31
11.71
- -
75.21
19.89
20.01
25.07
10.3
- -
- -
Profit Margin (%)
328.9
135.81
853.09
195.79
107.94
1,313.29
169.68
14.8
157.05
96.5
63.18
82.27
-224.71
- -
Working Capital
-220
-127
-253
-366
99
349
1,096
-62
24
59
638
1,683
2,146
1,995
LT Debt
- -
- -
- -
- -
- -
385
1,110
400
- -
- -
660
1,393
1,320
1,080
Total Equity
5,723
6,101
6,749
7,022
8,088
8,680
9,132
9,419
9,853
9,696
9,904
9,958
9,481
9,582
Return on Invested Capital (%)
2.14
4.22
-0.01
1.54
5.15
-0.37
- -
0.37
1.72
1.4
1.33
1.52
- -
- -
Return on Capital (%)
8.52
4.62
5.27
4.22
5.32
6.16
- -
0.67
3.22
1.66
1.5
2.21
- -
- -
Return on Common Equity (%)
17.58
10.37
13.06
9.42
10.72
10.87
7.37
0.5
5.38
3.3
2.24
2.91
-8.19
- -

Capital Structure

HKD

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
ST Debt
799
270
1,042
LT Borrowings
1,360
1,320
1,080
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
836
836
836
Market Capitalization
719
836
794

Working Capital

HKD

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
Total Current Assets
3,016
2,712
3,349
Cash, Cash Equivalents & STI
2,155
1,791
2,399
Accounts Receivable, Net
7
5
7
Inventories
584
642
661
Total Current Liabilities
1,092
566
1,354
Payables & Accruals
- -
- -
- -
ST Debt
799
270
1,042
Deferred Revenue
- -
- -
- -

Growth Rates

HKD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
3.58%
0.18%
-4.79%
Free Cash Flow
-294.22%
-86.72%
-282.56%
Net Income, GAAP
51.17%
123.07%
-374.25%
Sales/Revenue/Turnover
73.4%
2.62%
0.41%
Total Cash Common Dividend
- -
- -
-0.04%

Semi-annual Revenue

HKD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
286
2025
- -
- -
287
2026
- -
- -
- -

Semi-annual Earnings Per Share

HKD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
0.28
2025
- -
- -
-0.77
2026
- -
- -
- -

Semi-annual Dividends Per Share

HKD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
0.04
2025
- -
- -
0.04
2026
- -
- -
- -

Company Description

CEO
Kei Chi Lau
Full Time Employees
195
Sector
Finance
Industry
Real estate development
Address
Tower A, Southmark Hong Kong Hong Kong
IPO Date
Jul 31, 1998
Business
Multifield International Holdings Limited engages primarily in the manufacturing and sale of pharmaceutical raw materials and intermediates, specialty chemicals, and biopharmaceutical ingredients. Its core product portfolio includes active pharmaceutical ingredients (APIs), pharmaceutical intermediates, chemical reagents, and related specialty chemical products catering to pharmaceutical companies, chemical manufacturers, and biotechnology firms. The company operates principally in Greater China and serves global markets through its extensive production and distribution network. Founded in 2003 and headquartered in Hong Kong, Multifield International Holdings Limited also explores business segments involving contract manufacturing services and research and development in chemical and pharmaceutical technologies. In terms of recent corporate developments, Multifield has focused on expanding its strategic partnerships and enhancing its production capabilities to meet evolving global pharmaceutical demands. Over the past 1-2 years, the company has pursued operational optimization and capacity expansion initiatives, supported by targeted acquisitions and collaborations within the pharmaceutical and specialty chemical industries, aiming to strengthen its integrated supply chain and innovation capacity. These moves align with Multifield's strategic direction to broaden its product offerings and geographic reach while reinforcing its position as a leading supplier of high-quality chemical and pharmaceutical raw materials in Asia and internationally. The company operates across multiple business segments including pharmaceutical intermediates, APIs, specialty chemicals, contract manufacturing, and chemical research and development. Its customer base spans pharmaceutical manufacturers, chemical suppliers, biotech firms, and healthcare product developers. Multifield’s growth strategy includes leveraging its research capabilities and production scale in Hong Kong and Mainland China to serve both domestic and export markets. The company is publicly listed on the Hong Kong Stock Exchange under the ticker 0898.HK and maintains several subsidiaries for operational and market-specific activities.